1. Herriot Tabuteau - Founder, Chairman and CEO
Dr Herriot Tabuteau is the founder, chairman, and Chief Executive Officer of Axsome Therapeutics. With over 25 years of experience in the pharmaceutical and biotechnology industry, he has held several management and leadership positions in these sectors. Prior to founding Axsome Therapeutics, Dr Tabuteau served as Senior Vice President and Global Head of Clinical Development at Forest Laboratories. He also worked for Sanofi, Pfizer, Novartis, and Bristol-Myers Squibb in various clinical development and medical affairs roles.
2. Mark Jacobson - Executive Vice President and Chief Operating Officer
Mark Jacobson serves as Axsome Therapeutics' Executive Vice President and Chief Operating Officer, responsible for the company's operations, including clinical development, regulatory, commercialization, and manufacturing. He previously worked at Eli Lilly and Company for over 20 years, where he held various leadership positions in R&D, marketing, and commercial operations.
3. David Marek - Executive Vice President and Chief Business Officer
David Marek is the Executive Vice President and Chief Business Officer of Axsome. He is responsible for overseeing the company's business development and strategic planning initiatives. Prior to joining Axsome, he was the Executive Vice President of Corporate Development and Operations at PsyRx Inc.
4. Bill Redman - Senior Vice President and Chief Financial Officer
Bill Redman serves as Senior Vice President and Chief Financial Officer of Axsome Therapeutics. He has over 30 years of financial leadership experience in the healthcare industry, including serving as CFO for several biotechnology companies. He previously worked at Wyeth and Pfizer.
5. Cedric O'Gorman - Senior Vice President and Head of Clinical Development
Cedric O'Gorman is the Senior Vice President and Head of Clinical Development at Axsome. He oversees the company's clinical development programs, including managing the design, implementation, and execution of clinical trials. He previously worked at Pfizer, Novartis, and Eisai.
6. Mark Molden - Senior Vice President and General Counsel
Mark Molden serves as Senior Vice President and General Counsel at Axsome. He is responsible for overseeing the company's legal affairs and corporate governance. Prior to joining Axsome, he worked as an attorney at law firms specializing in corporate and securities law.
Lisa Sabath - Senior Vice President and Chief Commercial Officer
Lisa Sabath is the Senior Vice President and Chief Commercial Officer at Axsome. She oversees the company's commercialization strategies and operations, including product development and marketing. Prior to joining Axsome, she was the Vice President and General Manager of Neurology at AbbVie Inc.
Axsome Therapeutics Inc currently has 925 employees.
News about Axsome Therapeutics Inc Key Personnel |
The preliminary financial report reveals that Axsome Therapeutics generated $71 million in net product revenue during the fourth quarter of 2023, while the net revenue for the full year amounted to $204 million. Although these numbers show a significant increase in sales and a growing market presence, they must be analyzed in the context of the company s considerable net loss of $-202 million during the 12-month period ending in the third quarter of 2023. This cumulative loss resulted in a negative return on investment (ROI) of -53.6%.
The negative ROI figure raises concerns about Axsome Therapeutics ability to effectively manage its financial performance and generate profitable growth. Within the ...
|
